Rosuvastatin Reduces Ischemia-Reperfusion Injury in Patients With Acute Coronary Syndrome Treated With Percutaneous Coronary Intervention

被引：29

作者：

Jiang, Fangyong ^{[1
]}

Yang, Jin ^{[1
]}

Zhang, Linchao ^{[1
]}

Li, Rongshan ^{[1
]}

Zhuo, Liuan ^{[1
]}

Sun, Liping ^{[1
]}

Zhao, Qin ^{[1
]}

机构：

[1] Liuzhou Peoples Hosp, Dept Cardiol, Liuzhou 545006, Guangxi, Peoples R China

来源：

CLINICAL CARDIOLOGY | 2014年 / 37卷 / 09期

关键词：

C-REACTIVE PROTEIN; ELEVATION MYOCARDIAL-INFARCTION; NATRIURETIC PEPTIDE LEVELS; HEART-DISEASE; ATORVASTATIN PRETREATMENT; SUPEROXIDE-DISMUTASE; PRIMARY ANGIOPLASTY; ADMISSION PREDICT; ARTERY-DISEASE; STATIN THERAPY;

D O I：

10.1002/clc.22292

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Background: Statins reduce the incidence of cardiovascular events after percutaneous coronary intervention (PCI), but no clinical studies have investigated the role of statins in ischemia-reperfusion injury after PCI. Hypothesis: Rosuvastatin could reduce ischemia-reperfusion injury in patients with acute coronary syndrome treated with PCI. Objectives: We investigated the effects of rosuvastatin on ischemia-reperfusion injury in patients with acute coronary syndrome after PCI and evaluated short-term prognosis. Methods: Patients scheduled for emergent PCI were given either rosuvastatin for >= 6 months (10 mg/d, every night; n = 55) or no statins (control group; n = 65). Serum superoxide dismutase activity, malondialdehyde, brain natriuretic peptide (BNP), and high-sensitivity C-reactive protein (hs-CRP) were determined before and after PCI, as well as left ventricular ejection fraction and left ventricular end-diastolic volume. Major adverse cardiac events were observed at follow-ups for 6 months. Results: Superoxide dismutase activity in the rosuvastatin-treated group was higher than that of the control group; serum levels of malondialdehyde were lower. BNP and hs-CRP levels in the rosuvastatin-treated group were lower than that of the control group. Four weeks after PCI, the left ventricular ejection fraction in the treatment group was higher than that of the control group, and the left ventricular end-diastolic volume was lower. At the 6-month follow-up, there was no difference in major adverse cardiac events between the 2 groups. Conclusions: Rosuvastatin before PCI reduced ischemia-reperfusion injury in patients with acute coronary syndrome, which suggests the importance of application of rosuvastatin before PCI for early intervention.

引用

页码：530 / 535

页数：6

共 30 条

[1] Inflammatory biomarkers and coronary heart disease: from bench to bedside and back [J].

Biasillo, Gina ;

Leo, Milena ;

Della Bona, Roberta ;

Biasucci, Luigi Marzio .

INTERNAL AND EMERGENCY MEDICINE, 2010, 5 (03) :225-233

[2] Optimal medical therapy with or without PCI for stable coronary disease [J].

Boden, William E. ;

O'Rourke, Robert A. ;

Teo, Koon K. ;

Hartigan, Pamela M. ;

Maron, David J. ;

Kostuk, William J. ;

Knudtson, Merril ;

Dada, Marcin ;

Casperson, Paul ;

Harris, Crystal L. ;

Chaitman, Bernard R. ;

Shaw, Leslee ;

Gosselin, Gilbert ;

Nawaz, Shah ;

Title, Lawrence M. ;

Gau, Gerald ;

Blaustein, Alvin S. ;

Booth, David C. ;

Bates, Eric R. ;

Spertus, John A. ;

Berman, Daniel S. ;

Mancini, G. B. John ;

Weintraub, William S. ;

Boden, W. ;

O'Rourke, R. ;

Teo, K. ;

Hartigan, P. ;

Weintraub, W. ;

Maron, D. ;

Mancini, J. ;

Weintraub, W. ;

Boden, W. ;

O'Rourke, R. ;

Teo, K. ;

Hartigan, P. ;

Knudtson, M. ;

Maron, D. ;

Bates, E. ;

Blaustein, A. ;

Booth, D. ;

Carere, R. ;

Ellis, S. ;

Gosselin, G. ;

Gau, G. ;

Jacobs, A. ;

King, S., III ;

Kostuk, W. ;

Harris, C. ;

Spertus, J. ;

Peduzzi, P. .

NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (15) :1503-1516

[3] ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-Segment elevation myocardial infarction - Summary article - A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients with Unstable Angina) [J].

Braunwald, E ;

Antman, EM ;

Beasley, JW ;

Califf, RM ;

Cheitlin, MD ;

Hochman, JS ;

Jones, RH ;

Kereiakes, D ;

Kupersmith, J ;

Levin, TN ;

Pepine, CJ ;

Schaeffer, JW ;

Smith, EE ;

Steward, DE ;

Theroux, P ;

Gibbons, RJ ;

Alpert, JS ;

Faxon, DP ;

Fuster, V ;

Gregoratos, G ;

Hiratzka, LF ;

Jacobs, AK ;

Smith, SC .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2002, 40 (07) :1366-1374

[4] Protection by Atorvastatin Pretreatment in Patients Undergoing Primary Percutaneous Coronary Intervention Is Associated With the Lower Levels Of Oxygen Free Radicals [J].

Chen, Miao ;

Li, Hongwei ;

Wang, Yongliang .

JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2013, 62 (03) :320-324

[5] Reduction in BNP Levels With Treatment of Decompensated Heart Failure and Future Clinical Events [J].

Dhaliwal, Amandeep S. ;

Deswal, Anita ;

Pritchett, Allison ;

Aguilar, David ;

Kar, Biswajit ;

Souchek, Julianne ;

Bozkurt, Biykem .

JOURNAL OF CARDIAC FAILURE, 2009, 15 (04) :293-299

[6] Myocardial reperfusion injury: looking beyond primary PCI [J].

Froehlich, Georg M. ;

Meier, Pascal ;

White, Steven K. ;

Yellon, Derek M. ;

Hausenloy, Derek J. .

EUROPEAN HEART JOURNAL, 2013, 34 (23) :1714-+

[7] Processed B-Type Natriuretic Peptide Is a Biomarker of Postinterventional Restenosis in Ischemic Heart Disease [J].

Fujimoto, Hirotaka ;

Suzuki, Toru ;

Aizawa, Kenichi ;

Sawaki, Daigo ;

Ishida, Junichi ;

Ando, Jiro ;

Fujita, Hideo ;

Komuro, Issei ;

Nagai, Ryozo .

CLINICAL CHEMISTRY, 2013, 59 (09) :1330-1337

[8] Serum B-type natriuretic peptide levels on admission predict not only short-term death but also angiographic success of procedure in patients with acute ST-elevation myocardial infarction treated with primary angioplasty [J].

Grabowski, M ;

Filipiak, KJ ;

Karpinski, G ;

Wretowski, D ;

Rdzanek, A ;

Huczek, Z ;

Horszczaruk, GJ ;

Kochman, J ;

Rudowski, R ;

Opolski, G .

AMERICAN HEART JOURNAL, 2004, 148 (04) :655-662

[9] Anti-inflammatory effects of pioglitazone and/or sinivastatin in high cardiovascular risk patients with elevated high sensitivity C-reactive protein -: The PIOSTAT study [J].

Hanefeld, Markolf ;

Marx, Nikolaus ;

Pfuetzner, Andreas ;

Baurecht, Werner ;

Luebben, Georg ;

Karagiannis, Efstrathios ;

Forst, Thomas .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2007, 49 (03) :290-297

[10] High Sensitivity C-Reactive Protein and Outcomes Following Percutaneous Coronary Intervention in Contemporary Practice [J].

Herrmann, Joerg ;

Lennon, Ryan J. ;

Barsness, Gregory W. ;

Sandhu, Gurpreet S. ;

Gulati, Rajiv ;

Best, Patricia J. M. ;

Sorajja, Paul ;

Bresnahan, John F. ;

Mathew, Verghese ;

Bell, Malcolm R. ;

Prasad, Abhiram .

CIRCULATION-CARDIOVASCULAR INTERVENTIONS, 2012, 5 (06) :783-790

← 1 2 3 →